You are here

Press Release Archive

- Pfizer Declares a 29-cent Third-Quarter, 2007, Dividend

(BUSINESS WIRE)--The board of directors of Pfizer today declared a 29-cent third-quarter, 2007, dividend on the company's common stock, payable September 5, 2007, to shareholders of record at the close of business on August 10, 2007 Pfizer increased its quarterly dividend to 29 cents in the first quarter of 2007 as part of a series of actions the company is taking to enhance shareholder value. The third-quarter 2007 cash

- Pfizer Board of Directors to Initiate Face-to-Face Meetings with Company's Institutional Investors on Corporate Governance Policies and Practices

(BUSINESS WIRE)--Pfizer said today that members of its Board of Directors will invite its largest institutional shareholders to a meeting where they will have an opportunity to provide comments and perspective on the company’s governance policies and practices including executive compensation. Pfizer is the first company to initiate a regular meeting between its Board and institutional investors on governance. The Board will invite

- Pfizer Initiates Phase III Trial to Study Sunitinib Malate in Patients with Metastatic Colorectal Cancer

(BUSINESS WIRE)--Pfizer announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of sunitinib malate, in combination with a standard chemotherapy regimen, in patients with metastatic colorectal cancer (mCRC) - cancer originating in the colon that has spread to other parts of the body. In addition, new data from a Phase I study being presented this week at the World Congress on Gastrointestinal

- Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke

(BUSINESS WIRE)--Pfizer announced today that Lipitor (atorvastatin calcium) Tablets 80 mg reduced the risk of stroke, coronary heart disease events and major coronary events in type 2 diabetes patients who had no known coronary heart disease but who had experienced a recent stroke or mini-stroke, compared with placebo. The results are from a new analysis of the landmark Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)

- Exubera Demonstrated Pulmonary Safety with Blood Sugar Control in Three-Year Interim Analyses

(BUSINESS WIRE)--Results from three-year interim analyses of two ongoing long-term clinical trials showed that small mean declines in lung function in diabetes patients who took Exubera® (insulin human [rDNA origin]) Inhalation Powder reversed when Exubera was discontinued. Upon re-initiation of Exubera, lung function changes similar to first time users of Exubera were observed. The studies also showed that patients on an Exubera

- Pfizer's Lyrica Receives FDA Approval for Fibromyalgia Based on Expedited Review

(BUSINESS WIRE)--Pfizer announced today that the Food and Drug Administration (FDA) approved Lyrica® (pregabalin) capsules CV for the management of fibromyalgia, one of the most common chronic, widespread pain conditions in the United States. The approval of Lyrica, which received a priority review, represents a breakthrough for the more than six million Americans who suffer from this debilitating condition who previously had no FDA

- Pfizer Receives Approvable Letter From FDA For Maraviroc

(BUSINESS WIRE)--Pfizer announced today the U.S. Food and Drug Administration (FDA) issued an approvable letter for maraviroc, which is under review as a therapy for treatment-experienced patients infected with CCR5-tropic HIV-1. We continue our discussions with the FDA to address outstanding questions and finalize the product labeling as soon as possible. Pfizer is committed to making maraviroc available to the thousands of patients

- Pfizer Discontinues Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non-Small Cell Lung Cancer

(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) announced today the discontinuation of a development program in lung cancer for PF-3512676, an investigational compound, in combination with cytotoxic chemotherapy. This includes two Phase 3 clinical trials and two Phase 2 clinical trials. Pfizer licensed PF- 3512676 from Coley Pharmaceutical Group (NASDAQ: COLY) in 2005. A scheduled interim analysis of the Phase 3 clinical trials by an

- Slentrol, First Medication to Combat Canine Obesity, Now Available by Prescription

(BUSINESS WIRE)-- Pfizer Animal Health (NYSE: PFE) today announced that SLENTROL™ (dirlotapide), the first and only FDA-approved veterinary medication for the management of canine obesity, is now available by prescription in the United States. Slentrol was developed in response to the unmet need for a medication to help veterinarians and pet owners better manage canine obesity, an important medical condition that can lead

- Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at June 14 Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Olivier Brandicourt, Senior Vice President of Pfizer’s Pratt Business Unit, at the 28th Annual Goldman Sachs Health Care Conference on Thursday, June 14, at 8:40 a.m. Pacific Daylight Savings Time. To view and listen to the webcast, visit our web site homepage at and click on “the

- Pfizer to Advance Three Key Oncology Compounds into Phase 3 Trials in 2007, Company Tells Financial Analysts

(BUSINESS WIRE)--Pfizer Inc announced that it is advancing key compounds through clinical development at a meeting with financial analysts yesterday in connection with the American Society of Clinical Oncology annual meeting (ASCO) in Chicago. The company highlighted the following oncology compounds that are currently in Phase III trials as well as additional compounds expected to advance into Phase III trials in the next year: Compound

- New Data Show Pfizer's Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy

(BUSINESS WIRE)--Pfizer announced today that axitinib (AG-013736), an investigational oral, selective inhibitor of VEGFR 1, 2,3 (vascular endothelial growth factor receptors 1, 2, 3) combined with gemcitabine showed a trend towards prolonged overall survival (OS) in patients with advanced pancreatic cancer, compared with gemcitabine alone, according to preliminary data from a randomized Phase II trial. These data were presented at the

- Single-Agent SUTENT Prolonged Progression-Free Survival across All Advanced Kidney Cancer Patient Risk Groups, Including Those with Poorest Prognoses, Data Show

(BUSINESS WIRE)--Pfizer announced today that single-agent, oral SUTENT® (sunitinib malate) prolonged progression-free survival (PFS) across all patient risk groups, including those with the poorest prognoses for survival versus interferon-alfa (IFN-α), according to new data from the Phase III trial in the first-line treatment of advanced renal cell carcinoma (RCC). These data, along with Phase II studies of SUTENT in several tumor

- New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients with Non-Small Cell Lung Cancer

(BUSINESS WIRE)--Pfizer said today that clinical trials examining its different cancer-fighting approaches showed activity in patients with non-small cell lung cancer (NSCLC). Data on SUTENT® (sunitinib malate), as well as the investigational compounds CP-751,871 and axitinib (AG-013736), were presented at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting. “Pfizer is committed to developing innovative

- Pfizer and Express Scripts Sign Agreement

(BUSINESS WIRE)--Express Scripts, Inc. (NASDAQ: ESRX), and Pfizer Inc (NYSE: PFE), today announced an agreement providing for Pfizer’s participation in Express Scripts’ rebate program. Due to improved terms under the agreement, Express Scripts has added Lipitor® (atorvastatin calcium), Pfizer’s treatment for high cholesterol and the reduction of heart attack and stroke, to its national preferred

- UK Body Recommends Pfizer's Champix (varenicline) for Smokers

(BUSINESS WIRE)--Pfizer Inc announced today that the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom has recommended Champix (varenicline) for use on the National Health Service for adult smokers who have expressed a desire to quit. This gives smokers across England, Wales and Northern Ireland access to another important treatment option to help them quit smoking. In its Final Appraisal

- Pfizer Invites Public to View and Listen to Webcast of June 4 Pfizer Analyst Meeting at ASCO

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a meeting with investment analysts to be held on Monday, June 4, at 6:00 p.m. Central Daylight Savings Time, in connection with the Annual Meeting of the American Society of Clinical Oncology (ASCO). The analyst meeting will include presentations by Pfizer’s oncology leadership team. To view the webcast, visit our web site

- Pfizer's Growing Strength in Oncology

(BUSINESS WIRE)--At next week’s American Society of Clinical Oncology Meeting, Pfizer will present new information that underscores the depth and breadth of its oncology portfolio and the significant potential of projects advancing through the company’s research and development pipeline. Note: Details about key Pfizer presentations at ASCO are in the accompanying press release. Pfizer’s R&D pipeline in

- New Pfizer Oncology Data Across Numerous Cancer Types to be Presented at ASCO

(BUSINESS WIRE)--Pfizer said today that results showing potential across numerous types of cancer, such as melanoma, thyroid, liver, non-small cell lung (NSCLC), colorectal (CRC) and renal cell carcinoma (RCC) – a type of advanced kidney cancer – will be presented next week at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. “Each person with cancer responds differently to treatment

- Pfizer Will Immediately Seek to Appeal Lipitor Patent Ruling in Norway

(BUSINESS WIRE)--Pfizer Inc. said today that it will immediately seek to appeal a ruling by the Borgarting Court of Appeal in Oslo, Norway that four of Pfizer’s patents covering Lipitor are either invalid or not infringed by a proposed generic atorvastatin calcium product from Ranbaxy Laboratories. The Supreme Court of Norway will determine whether to hear the appeal. The Court of Appeal ruled that three Pfizer patents covering


Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.


Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.


If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.